Download the PDF Here
Failure to mulple Interferon-free direct anviral therapies: could chronic hepa,s C become incurable? J Vermehren1, J Dietz1, S Susser1, E Scho52, J Schaenberg3, E Zizer4, J Schulze zur Wiesch5, C Antoni6, P Wietzke-Braun7, C Niederau8, S Mauss9, JK Rockstroh10, B Müllhaupt11, RE Stauber12, S Zeuzem1, C Sarrazin1 1Medizinische Klinik 1, Universitätsklinikum Frankfurt, Germany, 2Charité Universitätsmedizin Berlin, Germany, 3Universitätsklinikum Mainz, Germany, 4Universitätsklinikum Ulm, Germany, 5Universitätsklinikum Eppendorf, Hamburg, Germany, 6Universitätsklinikum Mannheim, Germany, 7Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, 8Kath. Klinikum Oberhausen, Germany, 9Medizinisches Versorgungszentrum, Düsseldorf, Germany, 10Universitätsklinikum Bonn, Germany, 11UniversitätsSpital Zürich, Switzerland, 12Universitätsklinikum Graz, Austria Background & Aim Methods Chronic hepaRs C virus (HCV) infecon is a major health burden, affecRng approximately 71 million people worldwide who are at risk of developing chronic liver disease, cirrhosis and In a large resistance database, clinical and virological data were collected from paents who failed at least two DAA regimens. HCV NS3, NS5A and NS5B amplificaon and populaon- hepatocellular carcinoma.1 Following the introducRon of direct acRng anRviral agents (DAAs), the majority of paents with chronic HCV infecon can now be cured with only 8-12 based sequencing was performed. weeks of anRviral therapy. However, some paents do not achieve a sustained virologic response (SVR), regardless of the HCV genotype and/or DAA treatment involved. For these Retreatment was primarily based on guideline recommendaons, i.e. paents who failed on a regimen containing an NS5A inhibitor were retreated with a protease inhibitor and 2 paents, retreatment opons are limited. sofosbuvir, and paents who failed on a protease inhibitor-based regimen were retreated with an NS5A inhibitor and sofosbuvir.
[Show full text]